# Reviva Pharmaceuticals Holdings, Inc.: overview RVPH · OTC · CIK 1742927 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rvph.md) · [Financials](/companies/rvph/financials.md) · [Filings](/companies/rvph/filings.md) · [Insiders](/companies/rvph/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rvph/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TD Waterhouse Canada Inc.](/funds/1999606.md) | 2026-06-30 | $412 | 625 | | Unchanged | | [Purpose Unlimited Inc.](/funds/2115120.md) | 2026-06-30 | $259 | 405 | | Unchanged | | [EMC Capital Management](/funds/1847772.md) | 2026-06-30 | $3 | 6,696 | | Not compared | | [Mosley Wealth Management](/funds/2011849.md) | 2026-06-30 | $1 | 1 | | New +1 | | [Miller Global Investments, LLC](/funds/2099097.md) | 2026-06-30 | $1 | 1 | | New +1 | ## Recent filings [All 408 filings](/companies/rvph/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:53 ET | [10-Q](/filings/0001437749-26-027358.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027358 | | 2026-08-12 | 16:52 ET | [8-K](/filings/0001437749-26-027356.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-027356 | | 2026-05-13 | 16:43 ET | [10-Q](/filings/0001437749-26-016762.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016762 | | 2026-05-13 | 16:41 ET | [8-K](/filings/0001437749-26-016760.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-016760 | | 2026-05-13 | 08:03 ET | [8-K](/filings/0001437749-26-016538.md) | 3.01 Delisting notice; 8.01 Other events | 0001437749-26-016538 | | 2026-04-15 | 08:05 ET | [8-K](/filings/0001437749-26-012303.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-012303 | | 2026-03-30 | 06:11 ET | [8-K](/filings/0001437749-26-010140.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-010140 | | 2026-03-30 | 20:58 ET | [10-K](/filings/0001437749-26-010126.md) | Annual report, period 2025-12-31 | 0001437749-26-010126 | | 2026-03-24 | 16:15 ET | [SCHEDULE 13D/A](/filings/0001493152-26-012362.md) | Ownership report, active investor, amended | 0001493152-26-012362 | | 2026-03-19 | 16:17 ET | [8-K](/filings/0001437749-26-009063.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-009063 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010126.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1742927 - Tickers: RVPH - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:33 ET. No prices; not investment advice.